Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: Identification of an adenylyl cyclase 2 inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 2, 2013, Pages 276-287

  Conley, Jason M ^a   Brand, Cameron S ^b   Bogard, Amy S ^c   Pratt, Evan P S ^a   Xu, Ruqiang ^a   Hockerman, Gregory H ^a   Ostrom, Rennolds S ^c   Dessauer, Carmen W ^b   Watts, Val J ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; AMLEXANOX; CYCLIC AMP; DULOXETINE; ENZYME INHIBITOR; INDATRALINE; ISOENZYME; LORATADINE; MAPROTILINE; NKY 80; OXYMETHOLONE; PHORBOL 13 ACETATE 12 MYRISTATE; PROCHLORPERAZINE; THIORIDAZINE; TRANILAST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRONCHUS MUSCLE; DRUG IDENTIFICATION; DRUG RESEARCH; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; VALIDATION STUDY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ADENYLATE CYCLASE; ANIMALS; CELL MEMBRANE; CYCLIC AMP; ENZYME INHIBITORS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MYOCYTES, SMOOTH MUSCLE; SF9 CELLS; SMALL MOLECULE LIBRARIES; SPODOPTERA; TRANSFECTION;

EID: 84885987296     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207449     Document Type: Article

References (52)

1. Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520.
2. Berdeaux R and Stewart R (2012) cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration. Am J Physiol Endocrinol Metab 303: E1-E17.
3. Bogard AS, Adris P, and Ostrom RS (2012) Adenylyl cyclase 2 selectively couples to E prostanoid type 2 receptors, whereas adenylyl cyclase 3 is not receptor-regulated in airway smooth muscle. J Pharmacol Exp Ther 342: 586-595.
4. Bogard AS, Xu CF, and Ostrom RS (2011) Human bronchial smooth muscle cells express adenylyl cyclase isoforms 2, 4, and 6 in distinct membrane microdomains. J Pharmacol Exp Ther 337:209-217.
5. Braeunig JH, Schweda F, Han P.L., and Seifert R (2013) Similarly potent inhibition of adenylyl cyclase by P-site inhibitors in hearts from wild type and AC5 knockout mice. PLoS ONE 8:e68009.
6. Cumbay MG and Watts VJ (2001) Heterologous sensitization of recombinant adenylate cyclases by activation of D(2) dopamine receptors. J Pharmacol Exp Ther 297:1201-1209.
7. Degorce F, Card A, Soh S., Trinquet E, Knapik GP and Xie B (2009) HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr Chem Genomics 3:22-32.
8. Della Rocca G.J., van Biesen T, Daaka Y, Luttrell D.K., Luttrell LM, and Lefkowitz RJ (1997) Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi- and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem 272:19125-19132.
9. Dessauer CW (2002) Kinetic analysis of the action of P-site analogs. Methods Enzymol 345:112-126.
10. Drozdov I, Svejda B, Gustafsson B.I., Mane S., Pfragner R, Kidd M, and Modlin IM (2011) Gene network inference and biochemical assessment delineates GPCR pathways and CREB targets in small intestinal neuroendocrine neoplasia (Abstract). PLoS ONE 6:e22457.
11. Drummond GI and Severson DL (1979) Cyclic nucleotides and cardiac function. Circ Res 44:145-153.
12. Duerr EM, Mizukami Y, Ng A., Xavier RJ, Kikuchi H, Deshpande V, Warshaw A.L., Glickman J., Kulke MH, and Chung DC (2008) Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 15:243-256.
13. Erdorf M, Mou T-C, and Seifert R (2011) Impact of divalent metal ions on regulation of adenylyl cyclase isoforms by forskolin analogs. Biochem Pharmacol 82: 1673-1681.
14. Hanoune J and Defer N (2001) Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145-174.
15. Hellevuo K, Yoshimura M, Kao M., Hoffman PL, Cooper DMF, and Tabakoff B (1993) A novel adenylyl cyclase sequence cloned from the human erythroleukemia cell line. Biochem Biophys Res Commun 192:311-318.
16. Iwatsubo K, Bravo C, Uechi M., Baljinnyam E, Nakamura T, Umemura M., Lai L, Gao SM, Yan L, and Zhao X, et al. (2012) Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am J Physiol Heart Circ Physiol 302:H2622-H2628.
17. Iwatsubo K, Minamisawa S, Tsunematsu T., Nakagome M, Toya Y, Tomlinson J.E., Umemura S., Scarborough RM, Levy DE, and Ishikawa Y (2004) Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279:40938-40945.
18. Jacobowitz O and Iyengar R (1994) Phorbol ester-induced stimulation and phosphorylation of adenylyl cyclase 2. Proc Natl Acad Sci USA 91:10630-10634.
19. Kandel ER (2001) The molecular biology of memory storage: a dialogue between genes and synapses. Science 294:1030-1038.
20. Kim KS, Lee KW, Lee K.W., Im JY, Yoo JY, Kim SW, Lee J.K., Nestler EJ, and Han PL (2006) Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci USA 103:3908-3913.
21. Li S, Lee ML, Bruchas M.R., Chan GC, Storm DR, and Chavkin C (2006) Calmodulin-stimulated adenylyl cyclase gene deletion affects morphine responses. Mol Pharmacol 70:1742-1749.
22. Lin H, Sassano MF, Roth B.L., and Shoichet BK (2013) A pharmacological organization of G protein-coupled receptors. Nat Methods 10:140-146.
23. Ludwig MG and Seuwen K (2002) Characterization of the human adenylyl cyclase gene family: cDNA, gene structure, and tissue distribution of the nine isoforms. J Recept Signal Transduct Res 22:79-110.
24. Neveu WA, Allard JL, Raymond D.M., Bourassa LM, Burns SM, Bunn JY, Irvin C.G., Kaminsky DA, and Rincon M (2010) Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir Res 11:28. doi:10.1186/1465-9921-11-28.
25. Ohlstein EH and Berkowitz BA (1985) SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur J Pharmacol 108:205-208.
26. Okumura S, Kawabe J, Yatani A., Takagi G, Lee MC, Hong C, Liu J., Takagi I, Sadoshima J, and Vatner DE, et al. (2003) Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 93:364-371.
27. Patel TB, Du ZY, Pierre S, Cartin L., and Scholich K (2001) Molecular biological approaches to unravel adenylyl cyclase signaling and function. Gene 269: 13-25.
28. Pavan B, Biondi C, and Dalpiaz A (2009) Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today 14:982-991.
29. Pieroni JP, Harry A, Chen J.Q., Jacobowitz O., Magnusson RP, and Iyengar R (1995) Distinct characteristics of the basal activities of adenylyl cyclases 2 and 6. J Biol Chem 270:21368-21373.
30. Pierre S, Eschenhagen T, Geisslinger G., and Scholich K (2009) Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov 8:321-335.
31. Pinto C, Papa D, Hübner M, Mou T.C., Lushington GH, and Seifert R (2008) Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs. J Pharmacol Exp Ther 325:27-36.
32. Przybyla JA and Watts VJ (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332:710-719.
33. Rincon M and Irvin CG (2012) Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 8:1281-1290.
34. Robison GA, Butcher RW, and Sutherland EW (1968) Cyclic AMP. Annu Rev Biochem 37:149-174.
35. Roth DM, Gao MH, Lai N.C., Drumm J., Dalton N, Zhou JY, Zhu J, Entrikin D., and Hammond HK (1999) Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99:3099-3102.
36. Sadana R and Dessauer CW (2009) Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 17:5-22.
37. Seifert R, Lushington GH, Mou T.C., Gille A., and Sprang SR (2012) Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci 33:64-78.
38. Serezani CH, Ballinger MN, Aronoff D.M., and Peters-Golden M (2008) Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39: 127-132.
39. Suzuki Y, Shen TS, Poyard M, Best-Belpomme M, Hanoune J., and Defer N (1998) Expression of adenylyl cyclase mRNAs in the denervated and in the developing mouse skeletal muscle. Am J Physiol 274:C1674-C1685.
40. Tang T, Gao MH, Lai N.C., Firth AL, Takahashi T, Guo T, Yuan JXJ, Roth DM, and Hammond HK (2008) Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation 117:61-69.
41. Taussig R, Tang W-J, and Gilman AG(1994) Expression and purification of recombinant adenylyl cyclases in Sf9 cells, in Methods in Enzymology; Heterotrimeric G-protein effectors (Iyengar R ed) pp 95-108, Academic Press, Inc., San Diego, CA.
42. Tepe NM, Lorenz JN, Yatani A, Dash R., Kranias EG, Dorn GW, 2nd, and Liggett SB (1999) Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling. Biochemistry 38:16706-16713.
43. Torgan CE and Kraus WE (1996) Regulation of type II adenylyl cyclase mRNA in rabbit skeletal muscle by chronic motor nerve pacing. Am J Physiol 271: E253-E260.
44. Vadakkan KI, Wang H, Ko S.W., Zastepa E., Petrovic MJ, Sluka KA, and Zhuo M (2006) Genetic reduction of chronic muscle pain in mice lacking calcium/calmodulin-stimulated adenylyl cyclases. Mol Pain 2:7.
45. Wang H, Xu H, Wu L-J, Kim SS, Chen T, Koga K., Descalzi G, Gong B, Vadakkan KI, and Zhang X, et al. (2011) Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain (Abstract). Sci Transl Med 3: ra3.
46. Wei F, Qiu CS, Kim S.J., Muglia L., Maas JW, Pineda VV, Xu HM, Chen Z.F., Storm DR, and Muglia LJ, et al. (2002) Genetic elimination of behavioral sensitization in mice lacking calmodulin-stimulated adenylyl cyclases. Neuron 36:713-726.
47. Whitfield JF, Boynton AL, Macmanus J.P., Sikorska M., and Tsang BK (1979) Regulation of Cell-Proliferation by Calcium and Cyclic-AMP. Molecular and Cellular Biochemistry 27(3):155-179.
48. Willoughby D, Baillie GS, Lynch M.J., Ciruela A., Houslay MD, and Cooper DMF (2007) Dynamic regulation, desensitization, and cross-talk in discrete subcellular microdomains during beta2-adrenoceptor and prostanoid receptor cAMP signaling. J Biol Chem 282:34235-34249.
49. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H., Chen W, Hirotani S, Ishikawa Y, Sadoshima J, and Vatner SF (2007) Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130:247-258.
50. Yoshimura M and Cooper DMF (1993) Type-specific stimulation of adenylylcyclase by protein kinase C. J Biol Chem 268:4604-4607.
51. Yu SJ, Yu JK, Ge W.T., Hu HG, Yuan Y, and Zheng S (2011) SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 17:2028-2036.
52. Zhang JH, Chung TDY, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73.